← 返回

大麻素受体 2 通过限制 CD8(+) T 细胞和 NK 细胞的抗肿瘤活性,在非小细胞肺癌中发挥促肿瘤作用

英文原题:Cannabinoid receptor 2 plays a pro-tumorigenic role in non-small cell lung cancer by limiting anti-tumor activity of CD8(+) T and NK cells.

查看英文原题

Cannabinoid receptor 2 plays a pro-tumorigenic role in non-small cell lung cancer by limiting anti-tumor activity of CD8(+) T and NK cells.

PubMed 2023/01/09(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

大麻素(CB)受体(CB1和CB2)在癌细胞上表达,其表达影响多种肿瘤实体的癌变过程。肿瘤微环境(TME)中的细胞也表达CB受体,但其在肿瘤发展中的作用仍不清楚。

因此,我们在非小细胞肺癌(NSCLC)模型中研究了TME来源的CB1和CB2受体的作用。小鼠和人类NSCLC的TME中的白细胞表达CB受体,其中CB2的表达高于CB1。在肿瘤模型中,使用CB1敲除(CB1-/-)和CB2敲除(CB2-/-)小鼠,只有CB2的缺失,而非CB1的缺失,导致肿瘤负荷相对于野生型(WT)同窝小鼠减少。这伴随着CD8+ T细胞和NK 细胞的积聚和杀肿瘤活性增加,以及程序性死亡-1(PD-1)及其配体分别在淋巴样和髓样细胞上的表达增加。CB2-/-小鼠对抗PD-1治疗的反应显著优于WT小鼠。该治疗进一步增加了CB2-/-小鼠TME中细胞毒性淋巴细胞的浸润。

我们的研究结果表明,在NSCLC模型中,TME来源的CB2决定了免疫细胞向肿瘤的募集以及对抗PD-1治疗的反应性。CB2可作为免疫治疗的辅助靶点。

展开英文摘要原文

Cannabinoid (CB) receptors (CB 1 and CB 2 ) are expressed on cancer cells and their expression influences carcinogenesis in various tumor entities. Cells of the tumor microenvironment (TME) also express CB receptors, however, their role in tumor development is still unclear. We, therefore, investigated the role of TME-derived CB 1 and CB 2 receptors in a model of non-small cell lung cancer (NSCLC). Leukocytes in the TME of mouse and human NSCLC express CB receptors, with CB 2 showing higher expression than CB 1 .

In the tumor model, using CB 1 - (CB 1 -/- ) and CB 2 -knockout (CB 2 -/- ) mice, only deficiency of CB 2 , but not of CB 1 , resulted in reduction of tumor burden vs. wild type (WT) littermates.

This was accompanied by increased accumulation and tumoricidal activity of CD8 + T and natural killer cells, as well as increased expression of programmed death-1 (PD-1) and its ligand on lymphoid and myeloid cells, respectively. CB 2 -/- mice responded significantly better to anti-PD-1 therapy than WT mice. The treatment further increased infiltration of cytotoxic lymphocytes into the TME of CB 2 -/- mice.

Our findings demonstrate that TME-derived CB 2 dictates the immune cell recruitment into tumors and the responsiveness to anti-PD-1 therapy in a model of NSCLC. CB 2 could serve as an adjuvant target for immunotherapy.

论文信息

作者
Sarsembayeva A、Kienzl M、Gruden E、Ristic D、Maitz K、Valadez-Cosmes P、Santiso A、Hasenoehrl C
单位
Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria.Austria
文献类型
非美国政府资助研究
期刊
Frontiers in immunology2022
原文标识
PubMed 36700219 · DOI 10.3389/fimmu.2022.997115